Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Central Texas Neurology
mi
from
Round Rock, TX
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Central Texas Neurology
mi
from
Round Rock, TX
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
Integra Clinical Research
mi
from
San Antonio, TX
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
Integra Clinical Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated:  2/16/2016
MS Center at Evergreen
mi
from
Kirkland, WA
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00
Status: Enrolling
Updated: 2/16/2016
MS Center at Evergreen
mi
from
Kirkland, WA
Click here to add this to my saved trials
Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis
Randomized Control Trial Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Pilot Study
Status: Enrolling
Updated:  2/16/2016
University of Iowa
mi
from
Iowa City, IA
Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis
Randomized Control Trial Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Pilot Study
Status: Enrolling
Updated: 2/16/2016
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Resection Bed Post-Surgical Stereotactic Radiosurgery (SRS)
Efficacy of Post-Surgical Stereotactic Radiosurgery for Metastatic Brain Disease: A Randomized Trial
Status: Enrolling
Updated:  2/17/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Resection Bed Post-Surgical Stereotactic Radiosurgery (SRS)
Efficacy of Post-Surgical Stereotactic Radiosurgery for Metastatic Brain Disease: A Randomized Trial
Status: Enrolling
Updated: 2/17/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Reiki for the Management of Neuropathic Pain
Reiki for the Management of Neuropathic Pain in Service Members With Extremity Trauma
Status: Enrolling
Updated:  2/17/2016
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Reiki for the Management of Neuropathic Pain
Reiki for the Management of Neuropathic Pain in Service Members With Extremity Trauma
Status: Enrolling
Updated: 2/17/2016
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Transcranial Direct Current Stimulation, Improve Functional Motor Recovery, Affected Arm
Does Transcranial Direct Current Stimulation Improve Functional Motor Recovery in the Affected Arm-Hand in Patients After an Acute Ischemic Stroke: A Randomized Control Trial
Status: Enrolling
Updated:  2/18/2016
Oklahoma City VA Medical Center
mi
from
Oklahoma City, OK
Transcranial Direct Current Stimulation, Improve Functional Motor Recovery, Affected Arm
Does Transcranial Direct Current Stimulation Improve Functional Motor Recovery in the Affected Arm-Hand in Patients After an Acute Ischemic Stroke: A Randomized Control Trial
Status: Enrolling
Updated: 2/18/2016
Oklahoma City VA Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Energy Costs of Spasticity in Spinal Cord Injury: A Pilot Investigation
Energy Costs of Spasticity in Spinal Cord Injury: A Pilot Investigation
Status: Enrolling
Updated:  2/19/2016
Mcguire Va Medical Center
mi
from
Richmond, VA
Energy Costs of Spasticity in Spinal Cord Injury: A Pilot Investigation
Energy Costs of Spasticity in Spinal Cord Injury: A Pilot Investigation
Status: Enrolling
Updated: 2/19/2016
Mcguire Va Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Deep Brain Stimulation for Traumatic Brain Injury
Deep Brain Stimulation for Treatment of Severe Disability From Traumatic Brain Injury
Status: Enrolling
Updated:  2/19/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Deep Brain Stimulation for Traumatic Brain Injury
Deep Brain Stimulation for Treatment of Severe Disability From Traumatic Brain Injury
Status: Enrolling
Updated: 2/19/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Phase II Study of Lapatinib in Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related Tumors
Status: Enrolling
Updated:  2/19/2016
New York University School of Medicine
mi
from
New York, NY
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Phase II Study of Lapatinib in Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related Tumors
Status: Enrolling
Updated: 2/19/2016
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  2/19/2016
Clinical Research Facility
mi
from
Washington,
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 2/19/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  2/19/2016
Clinical Research Facility
mi
from
Centennial, CO
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 2/19/2016
Clinical Research Facility
mi
from
Centennial, CO
Click here to add this to my saved trials
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  2/19/2016
Clinical Research Facility
mi
from
Bradenton, FL
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 2/19/2016
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  2/19/2016
Clinical Research Facility
mi
from
Lake Barrington, IL
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 2/19/2016
Clinical Research Facility
mi
from
Lake Barrington, IL
Click here to add this to my saved trials
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  2/19/2016
Clinical Research Facility
mi
from
Lexington, KY
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 2/19/2016
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  2/19/2016
Clinical Research Facility
mi
from
Farmington Hills, MI
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 2/19/2016
Clinical Research Facility
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  2/19/2016
Clinical Research Facility
mi
from
Dayton, OH
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 2/19/2016
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  2/19/2016
Clinical Research Facility
mi
from
Franklin, TN
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 2/19/2016
Clinical Research Facility
mi
from
Franklin, TN
Click here to add this to my saved trials
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  2/19/2016
Investigator Site 102
mi
from
Brno,
An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)
A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 2/19/2016
Investigator Site 102
mi
from
Brno,
Click here to add this to my saved trials
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
Yale University
mi
from
New Haven, CT
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
Click here to add this to my saved trials
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
University of Rochester
mi
from
Rochester, NY
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
Baylor Institute of Immunology Research - Clinical Rheumatology
mi
from
Dallas, TX
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
Baylor Institute of Immunology Research - Clinical Rheumatology
mi
from
Dallas, TX
Click here to add this to my saved trials
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
Emory University
mi
from
Atlanta, GA
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluating the Effect of Diabetes Control Through Intensive Lifestyle Modifications on Diabetic Peripheral Neuropathy
Evaluation of the Effect of Intensive Diabetes Control Through Non-Surgical Intensive Lifestyle Modifications and Weight Reduction on Diabetic Peripheral Neuropathy
Status: Enrolling
Updated:  2/22/2016
Joslin Diabetes Center
mi
from
Boston, MA
Evaluating the Effect of Diabetes Control Through Intensive Lifestyle Modifications on Diabetic Peripheral Neuropathy
Evaluation of the Effect of Intensive Diabetes Control Through Non-Surgical Intensive Lifestyle Modifications and Weight Reduction on Diabetic Peripheral Neuropathy
Status: Enrolling
Updated: 2/22/2016
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating Intervention Responsiveness in People With Multiple Sclerosis
Evaluating Intervention Responsiveness in People With Multiple Sclerosis
Status: Enrolling
Updated:  2/22/2016
Motion Analysis Lab
mi
from
Baltimore, MD
Evaluating Intervention Responsiveness in People With Multiple Sclerosis
Evaluating Intervention Responsiveness in People With Multiple Sclerosis
Status: Enrolling
Updated: 2/22/2016
Motion Analysis Lab
mi
from
Baltimore, MD
Click here to add this to my saved trials
Dietary Intervention With the Modified Atkins Diet in Stroke Rehabilitation
Dietary Intervention in Stroke Recovery in the Acute Rehabilitation Setting With the Modified Atkins Diet.
Status: Enrolling
Updated:  2/22/2016
The Burke Rehabilitation Hospital
mi
from
White Plains, NY
Dietary Intervention With the Modified Atkins Diet in Stroke Rehabilitation
Dietary Intervention in Stroke Recovery in the Acute Rehabilitation Setting With the Modified Atkins Diet.
Status: Enrolling
Updated: 2/22/2016
The Burke Rehabilitation Hospital
mi
from
White Plains, NY
Click here to add this to my saved trials
Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH)
Effect of Statins on Cerebral Blood Flow After Subarachnoid Hemorrhage
Status: Enrolling
Updated:  2/23/2016
Washington Univeristy
mi
from
ST Louis, MO
Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH)
Effect of Statins on Cerebral Blood Flow After Subarachnoid Hemorrhage
Status: Enrolling
Updated: 2/23/2016
Washington Univeristy
mi
from
ST Louis, MO
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Hamzavi Dermatology/Dermatology Specialists of Canton
mi
from
Canton, MI
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Hamzavi Dermatology/Dermatology Specialists of Canton
mi
from
Canton, MI
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Hamzavi Dermatology
mi
from
Fort Gratiot, MI
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Hamzavi Dermatology
mi
from
Fort Gratiot, MI
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Lynderm Research
mi
from
Markham,
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Lynderm Research
mi
from
Markham,
Click here to add this to my saved trials
Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM to Transcranial Doppler as an Aid to Diagnosing Vasospasm
A Non-Randomized, Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM System to Transcranial Doppler as an Aid to Diagnosing Vasospasm
Status: Enrolling
Updated:  2/23/2016
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM to Transcranial Doppler as an Aid to Diagnosing Vasospasm
A Non-Randomized, Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM System to Transcranial Doppler as an Aid to Diagnosing Vasospasm
Status: Enrolling
Updated: 2/23/2016
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.
Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.
Status: Enrolling
Updated:  2/23/2016
Yale Physcian Building
mi
from
New Haven, CT
Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.
Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.
Status: Enrolling
Updated: 2/23/2016
Yale Physcian Building
mi
from
New Haven, CT
Click here to add this to my saved trials
Finding an Optimal Latency for Paired Associative Stimulation in People With Chronic Stroke
Effect of Different Interpulse Intervals of Paired Associative Stimulation on Cortical Excitability in People With Chronic Stroke
Status: Enrolling
Updated:  2/23/2016
University of Minnesota Clinical and Translational Science Institute
mi
from
Minneapolis, MN
Finding an Optimal Latency for Paired Associative Stimulation in People With Chronic Stroke
Effect of Different Interpulse Intervals of Paired Associative Stimulation on Cortical Excitability in People With Chronic Stroke
Status: Enrolling
Updated: 2/23/2016
University of Minnesota Clinical and Translational Science Institute
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated:  2/23/2016
Yale University School of Medicine
mi
from
New Haven, CT
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated: 2/23/2016
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated:  2/23/2016
Saint Louis University Medical Center
mi
from
St. Louis, MO
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated: 2/23/2016
Saint Louis University Medical Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated:  2/23/2016
Columbia University
mi
from
New York, NY
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated: 2/23/2016
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated:  2/23/2016
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated: 2/23/2016
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated:  2/23/2016
Cleveland Clinic
mi
from
Cleveland, OH
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated: 2/23/2016
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated:  2/23/2016
UT Southwestern Medical Center
mi
from
Dallas, TX
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated: 2/23/2016
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated:  2/23/2016
Hospital Ramos Mejia
mi
from
Buenos Aires,
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Status: Enrolling
Updated: 2/23/2016
Hospital Ramos Mejia
mi
from
Buenos Aires,
Click here to add this to my saved trials
Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)
Semantic Memory, Financial Capacity and Brain Perfusion in MCI
Status: Enrolling
Updated:  2/24/2016
Birmingham VA Medical Center, Birmingham, AL
mi
from
Birmingham, AL
Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)
Semantic Memory, Financial Capacity and Brain Perfusion in MCI
Status: Enrolling
Updated: 2/24/2016
Birmingham VA Medical Center, Birmingham, AL
mi
from
Birmingham, AL
Click here to add this to my saved trials
Effectiveness of Early Physical Therapy Intervention for Patients With Dizziness After a Sports-Related Concussion
A Feasibility Study for a Randomized Controlled Trial on the Effectiveness of Early Physical Therapy Intervention for Patients With Dizziness After a Sports-Related Concussion
Status: Enrolling
Updated:  2/24/2016
Walsh University
mi
from
North Canton, OH
Effectiveness of Early Physical Therapy Intervention for Patients With Dizziness After a Sports-Related Concussion
A Feasibility Study for a Randomized Controlled Trial on the Effectiveness of Early Physical Therapy Intervention for Patients With Dizziness After a Sports-Related Concussion
Status: Enrolling
Updated: 2/24/2016
Walsh University
mi
from
North Canton, OH
Click here to add this to my saved trials
Physical Therapy Intervention for Extended Physical Symptoms After a Sports-related Concussion
Physical Therapy Intervention for Extended Physical Symptoms After a Sports-related Concussion
Status: Enrolling
Updated:  2/24/2016
Walsh University
mi
from
North Canton, OH
Physical Therapy Intervention for Extended Physical Symptoms After a Sports-related Concussion
Physical Therapy Intervention for Extended Physical Symptoms After a Sports-related Concussion
Status: Enrolling
Updated: 2/24/2016
Walsh University
mi
from
North Canton, OH
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Cullman, AL
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Cullman, AL
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Fort Collins, CO
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Maitland, FL
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Maitland, FL
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
St. Petersburg, FL
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Grand Rapids, MI
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials